What happened with CAPR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Capricor Therapeutics focuses on Deramiocel, an experimental cell therapy for Duchenne muscular dystrophy, a disease that damages muscle function. Made from cells obtained from donated human hearts, it is designed to address inflammation and scarring involved in disease progression. Capricor also develops treatments and vaccines using exosomes, tiny particles released by cells. It has no products approved for sale and cannot market its candidates before regulatory approval.
Capricor develops and manufactures Deramiocel; Nippon Shinyaku holds exclusive distribution rights in the United States and Japan, with NS Pharma handling U.S. distribution alongside its parent. Nippon Shinyaku has paid upfront and development milestone payments. If Deramiocel is approved and sold, Capricor would receive a share of product revenue and could earn further milestone payments. This partner is expected to supply much of Capricor’s potential revenue.
Until commercial sales become possible, Capricor relies on equity financing, grants and partner payments. Its business depends on securing approval, obtaining donor hearts and scaling compliant manufacturing, followed by its distributor’s sales execution and insurers’ willingness to cover treatment.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Capricor’s results hinge on Deramiocel’s approval and commercialization with Nippon Shinyaku, its exclusive U.S. and Japanese distributor and source of substantial milestone payments and potential revenue sharing.
Sarepta Therapeutics sells drugs to Duchenne muscular dystrophy (DMD) patients Capricor hopes to treat with Deramiocel, though its mutation-targeted treatments may complement Capricor’s cell therapy for inflammation and scarring. Watch ELEVIDYS safety and eligibility news: its U.S. indication excluded non-ambulatory patients in November 2025.
Satellos Bioscience overlaps with Capricor in trying to slow DMD progression without restoring dystrophin: its oral candidate SAT-3247 aims to restore muscle regeneration, while Deramiocel targets inflammation and scarring. With no commercial product sales reported, watch SAT-3247 results from the adult TRAILHEAD trial and pediatric Phase 2 BASECAMP study.
Solid Biosciences is pursuing the same DMD patients as Capricor with SGT-003 gene therapy rather than a cell therapy aimed at inflammation and scarring. SGT-003’s development progress is the relevant signal for Deramiocel’s future competition; Solid’s disclosed programs remain investigational or preclinical, not products identified as generating sales.
Entrada Therapeutics is developing treatments for four DMD mutation groups that overlap with patients Capricor aims to treat using mutation-independent Deramiocel. Watch its candidates that skip exons 44, 45, 50 and 51—ENTR-601-44, -45, -50 and -51—for progress in those patient groups.
Precision BioSciences targets the same DMD population as Capricor with PBGENE-DMD gene editing, but its preclinical program is much earlier than Deramiocel, which is under U.S. FDA review. Watch PBGENE-DMD’s progress as a longer-term competing approach: Precision paused PBGENE-3243 to prioritize PBGENE-DMD and PBGENE-HBV.
Solid Biosciences Inc. earningsSLDB
Solid Biosciences’ report will show how its DMD gene therapy SGT-003 is progressing, and whether this potential competitor for the patients Capricor Therapeutics aims to treat is moving forward.
Look for SGT-003 development progress and clinical-trial updates. Advancement into clinical testing would mean another treatment for DMD patients is nearing testing in people, giving patients a potential alternative to Deramiocel; limited progress would mean less near-term pressure from this program, but would not establish Deramiocel’s efficacy or demand.
Sarepta Therapeutics,, Inc. earningsSRPT
Sarepta Therapeutics’ report will show how its DMD treatments are being used and what safety issues arise, giving context on other treatment options for patients Capricor Therapeutics hopes to treat.
Look at ELEVIDYS safety updates alongside who is eligible and how the treatment is being used. A safety profile and eligibility that support broader use would show existing treatment reaching patients Capricor also hopes to serve; safety concerns or tighter limits would constrain those options, but would not establish that patients will switch to Deramiocel.
Capricor Therapeutics Inc earningsThis company
Capricor Therapeutics has no approved product for sale, so this report will show whether revenue from its agreements is returning as the costs of advancing Deramiocel change.
Read revenue from agreements alongside research and development and administrative expenses and cash used in operations. More agreement revenue with spending under control would show the business beginning to fund work through those agreements; little revenue with heavy spending would show that existing funds are still carrying Deramiocel and the other programs.
